Hemp Enforcement, Modernization, and Protection Act

On January 22, 2026, Representative Griffith (R-VA) introduced HR7212, the Hemp Enforcement, Modernization, and Protection Act, which was referred to the House Committee on Energy and Commerce. The bill amends the Federal Food, Drug, and Cosmetic Act to create a federal regulatory framework for hemp-derived cannabinoid products, imposing current good manufacturing practices (CGMPs), third-party testing, labeling requirements, minimum age of sale (21), facility registration, product listing, and mandatory recall authority. The bill authorizes zero federal spending — it is a regulatory mandate, not a funding bill.

The money trail: HR7212 imposes compliance costs on manufacturers and sellers of hemp-derived cannabinoid products. It does not authorize any grants, tax credits, or direct appropriations. The cost burden falls on private operators. Firms already operating under FDA CGMPs for food, beverages, or dietary supplements face lower incremental costs than pure-play hemp CBD companies. The legislation does not appropriate funds for FDA enforcement — actual enforcement depends on subsequent appropriations.

Structural winners and losers: The bill favors large, established consumer packaged goods (CPG) companies with existing FDA-compliant manufacturing infrastructure (e.g., $GIS, $K, $SJM) that may enter or expand in the hemp-derived cannabinoid space. It disadvantages smaller pure-play hemp CBD operators with thin margins and no existing CGMP compliance. and have some hemp-derived cannabinoid product lines but derive most of their revenue from Canadian and international adult-use THC cannabis, which is unaffected by this bill. The bill does not change Schedule I status for THC cannabis, providing no catalyst for multi-state operators (MSOs) like $TCNNF, $CURLF, $GTBIF.

Based on real market data as of April 30, 2026: closed at $6.20, down 8.15% in the last 7 days and 4.17% in the last 30 days. closed at $1.13, down 4.24% in the last 7 days but up 18.95% in the last 30 days. The 30-day divergence (TLRY negative, CGC positive) suggests company-specific factors beyond this bill are driving price action. Neither stock shows material reaction tied to the January 22 introduction date, consistent with the bill's early-stage status and zero spending authorization.

Legislative timeline: HR7212 has only one action — referral to the House Energy and Commerce Committee on January 22, 2026. No hearings, markups, or further actions have occurred in over 3 months. The sponsor is a Republican House member (not a committee chair), with 5 cosponsors. Passage probability in the 119th Congress is low without broader cannabis reform momentum.